Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
04.08.2026 11:00
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience
Eli Lilly (NYSE:LLY) Stands Out as a High-Growth Momentum Leader
04.08.2026 09:50
Eli Lilly passes the CANSLIM growth screen with strong EPS and sales growth, high relative strength, but poor setup timing.
More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
04.08.2026 05:30
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Amplia Therapeutics partners with Lilly on lung cancer combination trial
04.08.2026 03:06
Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF) has signed a clinical collaboration agreement with Eli Lilly and Company to evaluate its lead drug narmafotinib alongside Lilly’s next-generation KRAS G12C inhibitor olomorasib in patients with advanced non-small cell lung cancer (NSCLC). The...
Inspire Medical Systems Q2 Earnings Call Highlights
04.08.2026 00:03
Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting
Dow Jones Futures Due As Trump Calls Off Iran Attacks; SpaceX, AMD, Sandisk, Eli Lilly Earnings Loom
02.08.2026 13:32
President Trump said he's holding off on massive new Iran attacks. SpaceX, AMD, Sandisk, Lilly earnings loom as market rally attempt begins.
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
02.08.2026 12:15
Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.
NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court
01.08.2026 00:52
The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.
Weight Loss Drug Stocks Slump Below Key Levels. What Ozempic Maker Said.
31.07.2026 17:14
Novo Nordisk and Eli Lilly, the firms behind Ozemic, Wegovy and Zepbound, faced selling pressure on Friday.
Sleep-Apnea Biotech Apnimed Shares Jump After Upsized US IPO
31.07.2026 15:58
(Bloomberg) -- Apnimed Inc., a late-stage drug developer focused on sleep apnea rose 6.3% on Friday after raising $192 million in an upsized US initial public offering.Most Read from BloombergSingapore's Gated Island for the Rich Is Marred by Decayed HomesAnthropic AI Models Hacked Three Organizations During TestsMicrosoft’s $450 Billion Jump Is Biggest in Stock Market HistoryChip Stocks Post Biggest Advance Since April 2025: Markets WrapUS Strikes Iran Again as Conflict Spreads Across Middle Ea
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
31.07.2026 15:51
Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's Novo Nordisk announced overnight that its experimental cardiovascular drug, ziltivekimab — to treat heart disease, kidney disease and inflammation — failed in the late-stage trial.
AMD Stock Rebounds With Chips Ahead Of Q2 Report; SpaceX Earnings, Lockup Expiration Loom Large
31.07.2026 14:59
AMD stock keeps its latest pullback contained compared with many other chip stocks as its second-quarter earnings report looms large.
Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial
31.07.2026 14:56
The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.
The Signs Before Eli Lilly Stock Surged Were All On The Record
31.07.2026 14:26
Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.
LLY Stock: Collect 12% Now, In Exchange For Capping Upside At 15%
31.07.2026 14:07
Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
31.07.2026 13:15
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
31.07.2026 13:00
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure
31.07.2026 12:00
Ratio Therapeutics, Inc. (Ratio), a clinical-stage pharmaceutical company developing best-in-class radiopharmaceuticals for cancer treatment, today announced the closing of a $70 million Series C financing.
Resilience and Lilly to increase US medicines production with $750m investment
31.07.2026 09:00
The investment will support Resilience’s advanced manufacturing operations in Cincinnati.
Fulcrum Therapeutics: Buy It For The Strategic Reset
31.07.2026 08:13
Fulcrum trades below NCAV amid operational distress but boasts a fortress balance sheetâexplore why this deep-discount setup could outperform.